GlycoMimetics Inc

General ticker "GLYC" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $18.1M

GlycoMimetics Inc does not follow the US Stock Market performance with the rate: -37.4%.

Estimated limits based on current volatility of 8.3%: low 0.20$, high 0.23$

Factors to consider:

  • Current price 85.8% below estimated low
  • Earnings for 9 months up through Q3 are below our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2023-12-31 to 2025-12-30

  • 2023-12-31 to 2024-12-30 estimated range: [1.52$, 3.45$]
  • 2024-12-30 to 2025-12-30 estimated range: [1.32$, 3.10$]

Financial Metrics affecting the GLYC estimates:

  • Negative: Non-GAAP EPS, $ of -0.58 <= 0.10
  • Negative: Operating profit margin, % of -99.97 <= 1.03
  • Negative: Operating cash flow per share per price, % of -23.10 <= 2.35
  • Negative: negative Net income
  • Negative: Industry earnings per price (median), % of -26.04 <= 1.31
  • Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85

Similar symbols

Short-term GLYC quotes

Long-term GLYC plot with estimates

Financial data

YTD 2021-12-31 2022-12-31 2023-12-31
Operating Revenue $1.16MM $0.07MM $0.01MM
Operating Expenses $64.61MM $47.48MM $39.29MM
Operating Income $-63.45MM $-47.40MM $-39.28MM
Non-Operating Income $0.02MM $0.71MM $2.38MM
R&D Expense $47.49MM $28.39MM $20.07MM
Income(Loss) $-63.43MM $-46.69MM $-36.90MM
Profit(Loss) $-63.43MM $-46.69MM $-36.90MM
Stockholders Equity $81.60MM $42.93MM $38.41MM
Assets $94.35MM $51.81MM $45.32MM
Operating Cash Flow $-57.49MM $-46.46MM $-34.88MM
Capital expenditure $0.01MM $0.08MM $0.02MM
Investing Cash Flow $-0.01MM $-0.08MM $-0.02MM
Financing Cash Flow $10.72MM $4.16MM $28.82MM
Earnings Per Share* $-1.23 $-1.78 $-0.58

* EPS are Split Adjusted, recent splits may be reflected with a delay.